<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111447</url>
  </required_header>
  <id_info>
    <org_study_id>412889-6</org_study_id>
    <nct_id>NCT02111447</nct_id>
  </id_info>
  <brief_title>Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI</brief_title>
  <official_title>Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI: Comparative Study Using Propofol, Sevoflurane and Isoflurane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children who receive general anesthesia may become agitated (emergence delirium) in the
      recovery period. This occurs more often after inhalational anesthetics, particularly
      sevoflurane and desflurane than after propofol. However, agitation after anesthesia in
      children may be difficult to distinguish from pain; accordingly studies are ideally designed
      during MRI to obviate the contribution of pain during emergence. Airway complications have
      been reported after LMA and isoflurane more commonly than with IV propofol and nasal prongs.
      Whether the airway complications were due to the LMA or the isoflurane was unclear.
      Therefore, this study was designed to study the incidence of 1. agitation after sevoflurane
      compared with IV propofol and 2. airway complications after LMA or nasal prongs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      180 children, ASA physical status 1 or 2 will be recruited for elective MRI scan. Randomized
      after consent is obtained to one of four groups. Anxiety will be assessed preoperatively
      using the modified Yale preoperative anxiety scale. Children will be accompanied by one
      parent to MRI scanner where monitors are applied. All children will have anesthesia induced
      with nitrous oxide and oxygen followed by sevoflurane until IV is established. Thereupon,
      they will be managed by their randomization assignment. The propofol pump will be concealed
      at all times. If propofol was used, it will be disconnected from the patient and residual
      propofol in the line flushed so prevent unblinding the patient's assignment. A blinded
      observer will be present to evaluate the patient when emergence begins. The single blinded
      observer will follow the patient from the MRI scanner through recovery room evaluating vital
      signs as well as emergence delirium (using the PAED scale). A PAED score &gt; 12 at any time
      during emergence period will confirm the diagnosis of emergence delirium. After discharge
      from hospital, a post-discharge questionnaire will be completed at 12, 24 and 48 hours after
      discharge. All parents will be called to retrieve the questionnaire results after 48 hours
      after discharge from hospital.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough participants
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Delirium on Emergence</measure>
    <time_frame>WIthin 2 hours of emergence from anesthesia</time_frame>
    <description>Delirium on emergence will be assessed using the PAED scale by a blinded observer in the post anesthesia period. A score &gt;12 constitutes a diagnosis of delirium in children. The post anesthesia period is usually &lt;2 hours after anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Airway Complications</measure>
    <time_frame>WIthin 2 hours of emergence from anesthesia</time_frame>
    <description>All airway reflex responses including airway obstruction breath holding, coughing, laryngospasm, desaturation &lt;92% for &gt;15 s regardless of the cause, bronchospasm, secretions and hiccups</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Delirium on Emergence</condition>
  <arm_group>
    <arm_group_label>Sevoflurane, propofol, Nasal oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane, Propofol, LMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane, sevoflurane, LMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane, isoflurane, LMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol infusion with nasal oxygen</description>
    <arm_group_label>Sevoflurane, Propofol, LMA</arm_group_label>
    <arm_group_label>Sevoflurane, propofol, Nasal oxygen</arm_group_label>
    <other_name>Diprivan 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol infusion with an LMA</description>
    <arm_group_label>Sevoflurane, propofol, Nasal oxygen</arm_group_label>
    <other_name>1% Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane with an LMA</description>
    <arm_group_label>Sevoflurane, Propofol, LMA</arm_group_label>
    <arm_group_label>Sevoflurane, isoflurane, LMA</arm_group_label>
    <arm_group_label>Sevoflurane, sevoflurane, LMA</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane</intervention_name>
    <description>Isoflurane with an LMA</description>
    <arm_group_label>Sevoflurane, isoflurane, LMA</arm_group_label>
    <other_name>Forane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 2-12yrs,

          -  ASA Class I-II,

          -  Fasting,

          -  Unmedicated,

          -  Elective MRI scan

        Exclusion Criteria:

          -  Cognitive impairment,

          -  On psychotropic medications,

          -  Taking multiple (&gt;2) antiepileptic medications,

          -  Requiring endotracheal intubation for GA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerrold Lerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women And Childrens Hospital Of Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Heard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women And Childrens Hospital Of Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women and Chidren's Hospital Of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 9, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>July 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Jerrold Lerman</investigator_full_name>
    <investigator_title>Clinical Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>isoflurane</keyword>
  <keyword>propofol</keyword>
  <keyword>anesthesia</keyword>
  <keyword>MRI</keyword>
  <keyword>delirium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sevoflurane, Propofol, Nasal Oxygen</title>
          <description>After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Propofol: Propofol infusion with an LMA</description>
        </group>
        <group group_id="P2">
          <title>Sevoflurane, Propofol, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Sevoflurane: Sevoflurane with an LMA</description>
        </group>
        <group group_id="P3">
          <title>Sevoflurane, Sevoflurane, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA</description>
        </group>
        <group group_id="P4">
          <title>Sevoflurane, Isoflurane, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA
Isoflurane: Isoflurane with an LMA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>start study</population>
      <group_list>
        <group group_id="B1">
          <title>Sevoflurane, Propofol, Nasal Oxygen</title>
          <description>After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Propofol: Propofol infusion with an LMA</description>
        </group>
        <group group_id="B2">
          <title>Sevoflurane, Propofol, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Sevoflurane: Sevoflurane with an LMA</description>
        </group>
        <group group_id="B3">
          <title>Sevoflurane, Sevoflurane, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA</description>
        </group>
        <group group_id="B4">
          <title>Sevoflurane, Isoflurane, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA
Isoflurane: Isoflurane with an LMA</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Delirium on Emergence</title>
        <description>Delirium on emergence will be assessed using the PAED scale by a blinded observer in the post anesthesia period. A score &gt;12 constitutes a diagnosis of delirium in children. The post anesthesia period is usually &lt;2 hours after anesthesia.</description>
        <time_frame>WIthin 2 hours of emergence from anesthesia</time_frame>
        <population>none recruited that that group</population>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane, Propofol, Nasal Oxygen</title>
            <description>After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Propofol: Propofol infusion with an LMA</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane, Sevoflurane, LMA</title>
            <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA</description>
          </group>
          <group group_id="O3">
            <title>Sevoflurane, Propofol, LMA</title>
            <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Sevoflurane: Sevoflurane with an LMA</description>
          </group>
          <group group_id="O4">
            <title>Sevoflurane, Isoflurane, LMA</title>
            <description>After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA
Isoflurane: Isoflurane with an LMA</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Delirium on Emergence</title>
          <description>Delirium on emergence will be assessed using the PAED scale by a blinded observer in the post anesthesia period. A score &gt;12 constitutes a diagnosis of delirium in children. The post anesthesia period is usually &lt;2 hours after anesthesia.</description>
          <population>none recruited that that group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Airway Complications</title>
        <description>All airway reflex responses including airway obstruction breath holding, coughing, laryngospasm, desaturation &lt;92% for &gt;15 s regardless of the cause, bronchospasm, secretions and hiccups</description>
        <time_frame>WIthin 2 hours of emergence from anesthesia</time_frame>
        <population>none recruited to that group</population>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane, Propofol, Nasal Oxygen</title>
            <description>After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Propofol: Propofol infusion with an LMA</description>
          </group>
          <group group_id="O2">
            <title>Sevoflurane, Sevoflurane, LMA</title>
            <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA</description>
          </group>
          <group group_id="O3">
            <title>Sevoflurane, Propofol, LMA</title>
            <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Sevoflurane: Sevoflurane with an LMA</description>
          </group>
          <group group_id="O4">
            <title>Sevoflurane, Isoflurane, LMA</title>
            <description>After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA
Isoflurane: Isoflurane with an LMA</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Airway Complications</title>
          <description>All airway reflex responses including airway obstruction breath holding, coughing, laryngospasm, desaturation &lt;92% for &gt;15 s regardless of the cause, bronchospasm, secretions and hiccups</description>
          <population>none recruited to that group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Definition does not differ.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sevoflurane, Propofol, Nasal Oxygen</title>
          <description>After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Propofol: Propofol infusion with an LMA</description>
        </group>
        <group group_id="E2">
          <title>Sevoflurane, Sevoflurane, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA</description>
        </group>
        <group group_id="E3">
          <title>Sevoflurane, Propofol, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
Propofol: Propofol infusion with nasal oxygen
Sevoflurane: Sevoflurane with an LMA</description>
        </group>
        <group group_id="E4">
          <title>Sevoflurane, Isoflurane, LMA</title>
          <description>After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
Sevoflurane: Sevoflurane with an LMA
Isoflurane: Isoflurane with an LMA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>none study not completed due to facility issues</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Research Coordinator</name_or_title>
      <organization>GLA</organization>
      <phone>7163236570</phone>
      <email>tgensler@greatlakesanes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

